-
Two innovative bispecific antibodies of Regenerative Elements exhibit anti-tumor ability to treat patients with lung cancer and recurrent ovarian cancer
Time of Update: 2022-09-21
▲If you have any business needs, please long press to scan the QR code above, or▎ WuXi AppTec content team editorRegeneron Pharmaceuticals recently announced early data positive results for two research-under-research, innovative bispecific antibodies in phase 1/2 clinical trials.
-
Selenium is an essential element to improve resistance and prevent cancer! Eat more of these foods without fear of selenium deficiency
Time of Update: 2020-11-05
lack of selenium, you will be more likely than others to get 5 diseases in the professional field, selenium is well-known, both "heart protection God" praise, also known as the "king of cancer." , can antioxidant, delay aging, can improve immunity, can effectively protect the brain ...
-
Significantly extendo OS! Sanofi/Regenerative Element PD-1 Lung Cancer Phase III Clinical Early Termination.
Time of Update: 2020-08-21
Sanofi and Regenerative Yuan have announced that their PD-1 inhibitor Libtayo beat chemotherapy in a Phase III clinical trial of a first-line treatment for non-small cell lung cancer (NSCLC), significantly extending the total survival (OS) of patients.
-
mRNA Cancer Vaccine and Immune Checkpoint Suppression! BioNTech partnered with Regenerative Element to develop a BNT111/Libtayo combination to treat melanoma!
Time of Update: 2020-08-06
, the company recently announced a strategic partnership with Regeneron to conduct a clinical trial of a mRNA immunotherapy, BNT111 FixVac, in combination with the anti-PD-1 therapy Libtayo (cemiplimab) to treat melanoma.